Issy-les-Moulineaux, June 16, 2022 – Microsoft France today announces the launch of the Biotech Scaler program with its partners: Institut Curie and Cellenza. The initiative, intended for biotech and medicine, aims to accelerate their development by providing them with technological and analytical tools and supporting them in their investment research. 4 startups are already part of the program: MabSilico, WhiteLab Genomics, Ose Immunotherapeutics and Caranx.
The Biotech Scaler program brings together startups developing artificial intelligence platforms to identify new targets or drug candidates and biotech startups developing new platforms in immunotherapy, gene or cell therapy, to treat cancer, rare diseases or orphans. These companies, which are today at the forefront of innovation, nevertheless face long development cycles and require significant capital injections. To help them make rapid progress in their research and pursue their development, Microsoft France wanted to create a dedicated support program for them.
Institut Curie, a partner in the Biotech Scaler Program, will also guide startups from its incubator to this program. “Moving from promise to product is the biggest challenge for biotech. By integrating the Biotech Scaler program into our incubator, we provide an additional advantage to the companies resulting from our research to accelerate their development and provide patients with innovative treatments . The early choice of a good digital architecture is essential to be credible in discussions with investors, manufacturers or regulatory authorities and to differentiate oneself from the competition, which is global. » says Dr. Amaury Martin, Deputy Director responsible for technology transfer, industrial partnerships and data at the Institut Curie.
The Biotech scaler program thus offers participants:
- Technological support: through Founders Hub, Microsoft’s program for startups, Microsoft will offer startups in the Biotech Scaler Program free Azure credits, access to advice from our devops teams on their digital architecture and support for the development of their sheet road as they enter the scale-up phase, organized by Cellenza
- A mentoring program in search of investments: DNA Finance Investment & Advisory will guide startups in the program in their fundraising.
The Biotech Scaler Program is a tacit agreement that does not include any financial commitment or contractualization.
“The Biotech Scaler Program is a new type of grant program specifically designed to meet the needs of biotech startups whose development may require extremely rapid scaling. We provide them with a set of digital tools and skills that enable them to meet these needs. » says Charles Calestroupat, director of the public sector at Microsoft France.
Press contact: Hopscotch Agency for Microsoft
Amélie Rochette – 01 41 34 20 27– [email protected]